Stock detail
Gyre Therapeutics (GYRE) stock price, chart, and key data
View Gyre Therapeutics stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Gyre Therapeutics
GYRE · XNAS
$6.78
+0.44%
+$0.03
Key metrics
52-week range
$1.75 - $0.00
Close price
$6.75
Market cap
$736.9M
P/E ratio
-35
Beta
0.74
About the company
Gyre Therapeutics Inc
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$19.00
2
Buy
/ 2
Recent calls
08/10/2026
Noble Financial
Robert LeBoyer
Buy · Price target $20.00
08/07/2026
H.C. Wainwright
Matthew Keller
Buy · Price target $18.00
10/10/2025
Jefferies
Roger Song
Buy · Price target $16.00
Ticker holders
Review politician disclosures and insider transactions in tabs.
No holder data is available for this category yet.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app